Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.
about
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.Evaluation of dosing strategy for pembrolizumab for oncology indications.Commentary on Pharmacometrics for Immunotherapy.Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma.Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients with Urothelial Carcinoma.Dose Finding Versus Speed in Seamless Immuno-Oncology Drug Development.
P2860
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Population Pharmacokinetic/Pha ...... mab-Treated Advanced Melanoma.
@en
Population Pharmacokinetic/Pha ...... mab-Treated Advanced Melanoma.
@nl
type
label
Population Pharmacokinetic/Pha ...... mab-Treated Advanced Melanoma.
@en
Population Pharmacokinetic/Pha ...... mab-Treated Advanced Melanoma.
@nl
prefLabel
Population Pharmacokinetic/Pha ...... mab-Treated Advanced Melanoma.
@en
Population Pharmacokinetic/Pha ...... mab-Treated Advanced Melanoma.
@nl
P2093
P2860
P356
P1476
Population Pharmacokinetic/Pha ...... mab-Treated Advanced Melanoma.
@en
P2093
A G Kondic
A Lindauer
A Sostelly
D C Turner
D P de Alwis
J Elassaiss-Schaap
K Mayawala
M S Chatterjee
P2860
P356
10.1002/PSP4.12140
P577
2016-11-29T00:00:00Z